WO2009038106A1 - アラニルチロシンを含有する経口剤 - Google Patents
アラニルチロシンを含有する経口剤 Download PDFInfo
- Publication number
- WO2009038106A1 WO2009038106A1 PCT/JP2008/066808 JP2008066808W WO2009038106A1 WO 2009038106 A1 WO2009038106 A1 WO 2009038106A1 JP 2008066808 W JP2008066808 W JP 2008066808W WO 2009038106 A1 WO2009038106 A1 WO 2009038106A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral administration
- alanyltyrosine
- administration drug
- drug containing
- tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本発明は、アラニルチロシンまたはその塩を有効成分として含有する、即効性血中チロシン濃度上昇型経口剤を提供する。該経口剤は、生体内のチロシン含量を高め、速やかにチロシンの摂取効果が得られる。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-242955 | 2007-09-19 | ||
| JP2007242955 | 2007-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009038106A1 true WO2009038106A1 (ja) | 2009-03-26 |
Family
ID=40467916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/066808 Ceased WO2009038106A1 (ja) | 2007-09-19 | 2008-09-18 | アラニルチロシンを含有する経口剤 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009038106A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019059356A1 (ja) * | 2017-09-25 | 2019-03-28 | 花王株式会社 | 高吸収型経口チロシン製剤 |
-
2008
- 2008-09-18 WO PCT/JP2008/066808 patent/WO2009038106A1/ja not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| MAHER,TJ ET AL.: "Use of parenteral dipeptides to increase serum tyrosine levels and to enhance catecholamine-mediated neurotransmission.", J. PHARM. SCI., vol. 79, no. 8, August 1990 (1990-08-01), pages 685 - 687 * |
| REINSTEIN,DK ET AL.: "Dietary tyrosine suppresses the rise in plasma corticosterone following acute stress in rats.", LIFE SCI., vol. 37, no. 23, 9 December 1985 (1985-12-09), pages 2157 - 2163 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019059356A1 (ja) * | 2017-09-25 | 2019-03-28 | 花王株式会社 | 高吸収型経口チロシン製剤 |
| JP2019059678A (ja) * | 2017-09-25 | 2019-04-18 | 花王株式会社 | 高吸収型経口チロシン製剤 |
| JP7008452B2 (ja) | 2017-09-25 | 2022-01-25 | 花王株式会社 | 高吸収型経口チロシン製剤 |
| US11278586B2 (en) | 2017-09-25 | 2022-03-22 | Kao Corporation | Highly absorbable oral tyrosine formulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006096434A3 (en) | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders | |
| WO2007087068A3 (en) | Inhibitors of tyrosine kinases and uses thereof | |
| WO2007093450A3 (en) | Deuterated catecholamine derivatives and medicaments comprising said compounds | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| EP2371853A3 (en) | Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment | |
| WO2009048148A1 (ja) | シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤 | |
| WO2007093624A3 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| EA201070121A1 (ru) | Лекарственная форма, содержащая слитый белок glp-1-fc | |
| EP2545939A3 (en) | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring | |
| SI2269583T1 (sl) | Farmacevtski pripravek, ki vsebuje hidroklorotiazid in telmisartan | |
| WO2006119958A3 (en) | Use of flibanserin in the treatment of chronic pain | |
| CY1108794T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| WO2009004995A1 (ja) | 生理活性物質を定着および発現させる方法 | |
| WO2008076954A3 (en) | Heterocycle compounds and methods of use thereof | |
| WO2010005980A8 (en) | Tacrolimus for improved treatment of transplant patients | |
| WO2007012022A3 (en) | Unit dose form with ibuprofen-famotidine admixture | |
| WO2008112773A3 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension | |
| EA201170117A1 (ru) | Противоаллергические биополимеры морского происхождения | |
| WO2008079610A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
| WO2009099553A3 (en) | Use of kinase inhibitor in treatment of atherosclerosis | |
| WO2009068708A3 (es) | Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo | |
| EA200901237A1 (ru) | Применение димирацетама при лечении хронической боли | |
| BRPI0720230B8 (pt) | formulação nutricional oralmente administrável, uso da formulação, e, composição | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| WO2007018588A8 (en) | Stable pharmaceutical composition comprising linezolid form iv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08831661 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08831661 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |